CSS
KITE

Cubist Systematic Strategies’s Kite Pharma, Inc. KITE Stock Holding History

Cubist Systematic Strategies’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,782
Closed -$185K – 2131
2017
Q2 		$185K Sell
1,782
-636
-26% -$51.9K 0.01% 1318
2017
Q1 		$190K Sell
2,418
-4,911
-67% -$304K 0.01% 1210
2016
Q4 		$329K Buy
+7,329
New +$360K 0.03% 908
2016
Q1 		– Sell
-9,859
Closed -$608K – 1978
2015
Q4 		$608K Buy
+9,859
New +$694K 0.04% 723

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Cubist Systematic Strategies's KITE Position: Q3 2017 in Review

Cubist Systematic Strategies sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 1,782 shares — an estimated $185K sold.

Cubist Systematic Strategies first reported a position in KITE in Q4 2015 and held it in 4 quarters. The position peaked at $608K in Q4 2015. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Cubist Systematic Strategies reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,782 Kite Pharma, Inc. shares in Q3 2017, an estimated $185K.
  • Cubist Systematic Strategies first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 4 quarters.
  • Cubist Systematic Strategies's Kite Pharma, Inc. position peaked at $608K in Q4 2015.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Cubist Systematic Strategies's 13F filing for Q3 2017, filed 14 Nov 2017.